Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Transl Oncol ; 20(7): 936, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29546594

RESUMO

In the original version of this article the figure captions of Figs. 1 and 2 were interchanged.

2.
Clin Transl Oncol ; 20(1): 84-88, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29098554

RESUMO

Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiation therapy is an essential component of curative-intent of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.


Assuntos
Carcinoma/diagnóstico , Carcinoma/terapia , Neoplasias Nasofaríngeas/diagnóstico , Neoplasias Nasofaríngeas/terapia , Humanos , Carcinoma Nasofaríngeo
3.
Clin Transl Oncol ; 20(7): 899-905, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29159793

RESUMO

PURPOSE: To report the outcomes of a cohort of very elderly muscle-invasive bladder cancer (MIBC) patients treated with contemporary 3D-conformal radiation therapy (3D-CRT) with or without concurrent chemotherapy, after transurethral resection of bladder tumor (TURBT). METHODS: From February 2010 to January 2014, a total of 41 patients older than 75 years, with T2-3 N0-1 high-grade MIBC, a Karnofsky index (KI) of at least 90% and/or a Barthel scale score of at least 95, were treated with TURBT followed by radiotherapy (RT) with or without chemotherapy, and were prospectively followed-up. RESULTS: The mean age of patients was 82 years (range 76-88). Median follow-up was 47 months for surviving patients. Mean Charlson Comorbidity Index (CCI) score was 5 points. 28 patients (68.29%) were T2N0. All received 3D-CRT to a mean dose of 60 Gy (range 48.6-66 Gy), and chemotherapy was delivered to 34 patients (83%). Cause-specific survival (CSS) was 86 and 78.8% at 1 and 5 years, respectively. Patients achieving a complete response lived longer (48 vs 14 m, p = 0.036) than those with a progressive disease, who were more likely to die from cancer than from other causes (HR 3.865, IC95% 1.562-9.562). Dead patients had a longest treatment time (mean 56.78 vs 48.91 days, p = 0.019) than survivors. CONCLUSION: RT with contemporary 3D-CRT techniques after TURBT for MIBC in elderly patients is feasible and well-tolerated. Achieving a maximal response and shortening the total radiation treatment time may improve outcomes and quality of life.


Assuntos
Neoplasias Musculares/radioterapia , Recidiva Local de Neoplasia/radioterapia , Qualidade de Vida , Radioterapia Conformacional/mortalidade , Neoplasias da Bexiga Urinária/radioterapia , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Feminino , Seguimentos , Humanos , Masculino , Neoplasias Musculares/patologia , Recidiva Local de Neoplasia/patologia , Tratamentos com Preservação do Órgão , Prognóstico , Taxa de Sobrevida , Neoplasias da Bexiga Urinária/patologia
4.
Clin Transl Oncol ; 11(2): 114-6, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19211378

RESUMO

Oxaliplatin has been classified as an irritant drug. Less than 10 cases of oxaliplatin extravasation through a central venous access have been described to date. We present a case of extravasation through a central venous access, of the highest dose (165 mg) of oxaliplatin reported to date. We confirmed the irritant effect, and full recovery from toxicity was achieved. We describe the treatment administered and offer a review of literature.


Assuntos
Antineoplásicos/efeitos adversos , Extravasamento de Materiais Terapêuticos e Diagnósticos/diagnóstico , Compostos Organoplatínicos/efeitos adversos , Adenocarcinoma/tratamento farmacológico , Idoso , Antineoplásicos/administração & dosagem , Extravasamento de Materiais Terapêuticos e Diagnósticos/patologia , Extravasamento de Materiais Terapêuticos e Diagnósticos/terapia , Feminino , Humanos , Compostos Organoplatínicos/administração & dosagem , Oxaliplatina , Neoplasias Retais/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA